• Coronavirus

Dr. Steven Quay on Newsmax TV

Play Video
  • Newsmax TV
  • February 19th, 2021

Dr. Stephen Quay, a scientist overseeing two COVID-19 trials, discusses the timeline for the U.S. returning to normalcy, noting positive trends in cases and deaths in New York. He highlights advancements in vaccine distribution, including Pfizer’s revelation that their vaccine no longer requires extreme cold storage and the potential effectiveness of just one dose. Quay explains that ongoing research and trials inform these developments, emphasizing the importance of understanding vaccine immunity and addressing compliance issues. Regarding concerns about vaccine variants and the need for multiple doses, Quay suggests that while variants are important to monitor, the current vaccines should provide substantial immunity against most variants, with potential need for periodic boosters akin to the annual flu shot due to COVID-19 likely becoming endemic.

For more information about Newsmax click here.

  • Tags: covid, COVID-19, covid19, Dr quay, dr steven quay, Newsmax, Newsmax TV, Steven Quay, Vaccine

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Results: Endoxifen Reduces Breast Density

November 8, 2024

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Taiwan based scientist makes case for lab origin for COVID

November 7, 2024

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

October 31, 2024

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Join Dr. Quay’s ElevatorMedicine™ and get FREE, QUICK TIPS for better living, health, and wellness that take less time than riding an elevator!